These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22023047)

  • 1. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.
    Wang RE; Niu Y; Wu H; Hu Y; Cai J
    Anticancer Agents Med Chem; 2012 Jan; 12(1):76-86. PubMed ID: 22023047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.
    Zhu L; Ding Z; Li X; Wei H; Chen Y
    Mol Imaging; 2020; 19():1536012120934957. PubMed ID: 32862776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.
    Zou M; Zhang L; Xie Y; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):239-46. PubMed ID: 22263803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
    Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
    Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neovasculature homing motif NGR: more than meets the eye.
    Corti A; Curnis F; Arap W; Pasqualini R
    Blood; 2008 Oct; 112(7):2628-35. PubMed ID: 18574027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of NGR peptide-based agents for tumor imaging.
    Wang RE; Niu Y; Wu H; Amin MN; Cai J
    Am J Nucl Med Mol Imaging; 2011; 1(1):36-46. PubMed ID: 23133793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
    Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
    Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of
    Satpati D; Sharma R; Sarma HD; Dash A
    Chem Biol Drug Des; 2018 Mar; 91(3):781-788. PubMed ID: 29130625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
    Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
    PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminopeptidase N (CD13) targeted MR and NIRF dual-modal imaging of ovarian tumor xenograft.
    Meng Y; Zhang Z; Liu K; Ye L; Liang Y; Gu W
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():968-974. PubMed ID: 30274135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug delivery and penetration into solid tumors.
    Corti A; Pastorino F; Curnis F; Arap W; Ponzoni M; Pasqualini R
    Med Res Rev; 2012 Sep; 32(5):1078-91. PubMed ID: 21287572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of tumor endothelial cells and drug delivery.
    Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
    Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
    J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.